All In Biotech

NDA 011870 · Salix Pharms

Diuril

Chlorothiazide · Oral · Thiazide Diuretic

Discontinued

Last checked: Nov 20, 2026Latest source record: Jun 10, 2009 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1961

Oct 6, 1961

Approved uses

1

Original approval plus efficacy supplements

Registered trials

330

91 Phase 3, 10 recruiting

FAERS reports

1,263

1,011 serious, 199 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 1, 2021.

INDICATIONS AND USAGE DIURIL is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. DIURIL has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. DIURIL is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. Use in Pregnancy - Routine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy (see PRECAUTIONS, Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the gravid uterus, is properly treated through elevation of the lower extremities and use of support stockings. Use of diuretics to lower intravascular volume in this instance is illogical and unnecessary. During normal pregnancy there is hypervolemia which is not harmful to the fetus or the mother in the absence of cardiovascular disease. However, it may be associated with edema, rarely generalized edema. If such edema causes discomfort, increased recumbency will often provide relief. Rarely this edema may cause extreme discomfort which is not relieved by rest. In these instances, a short course of diuretic therapy...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 6, 1961 Original approval · Type 3 - New Dosage Form
1 products under this application
  • DIURIL · CHLOROTHIAZIDE 250MG/5ML · SUSPENSION, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Chlorothiazide" as an intervention, any sponsor and status, largest first.

All 330 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use88
  • dyspnoea81
  • pyrexia79
  • diarrhoea73
  • hypotension71
  • drug ineffective66
  • pneumonia63
  • respiratory failure62
  • pain59
  • vomiting52
  • death50
  • cough48

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200419
200525
200619
200725
200816
200927
201035
201155
201240
201353
201456
201555
201684
201763
2018120
2019107
2020108
202192
202293
202361
202443
202541
202626

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Feb 10, 2026

    Diuril, Oral Suspension, 250 mg/5mL (NDC 65649-311-12).

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Diuril (Chlorothiazide)

2024 spending

$21K

Beneficiaries

85

236 claims

Per beneficiary

$247

$0.31 per unit

View as table
YearSpending
2020$20,134
2021$24,603
2022$30,867
2023$17,639
2024$20,999

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 50 on PubMed

Sponsor: Salix Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.